Update Regarding Forward Guidance

Summary by AI BETAClose X

Renalytix plc clarified its forward revenue guidance, stating that it does not fully incorporate the potential impact of its recent collaboration with Tempus AI, Inc. Due to the early stage of the collaboration, the company is unable to predict the revenue contributions from this relationship. The company intends to provide shareholders with updates on the Tempus collaboration in the future. The kidneyintelX.dkd test has full reimbursement established by Medicare at $950 per reportable result.

Disclaimer*

UK 100

Latest directors dealings